



Amendments to the Claims

1. (Currently amended) A compound of formula (I):



or pharmaceutically acceptable salts, or solvates thereof, wherein:

R⁶, R⁷ and R⁹ are independently selected from H, R, OH, OR, SH, SR, NH₂, NHR, NRR', nitro, Me₃Sn and halo;

where R and R' are independently selected from C₁₋₇ alkyl, heterocyclyl having 3 to 20 ring atoms of which 1 to 10 are ring heteroatoms independently selected from the group consisting N, O and S and aryl or heteroaryl having 5 to 20 ring atoms, the heteroaryl groups having one or more heteratoms independently selected from the group consisting of N, O and S;

R⁸ is selected from H, R, OH, OR, SH, SR, NH₂, NHR, N[[H]]RR', nitro, Me₃Sn and halo, or the compound is a dimer with each monomer being of formula (I), where the R⁸ groups of each monomers form together a dimer bridge having the formula -X-R"-X- linking the monomers, where R" is a C₃₋₁₂ alkylene group, which chain may be interrupted by one or more heteroatoms selected from the group consisting of O, S, and NH, and/or aromatic rings selected from the

group consisting of benzene and pyridine, and each X is independently selected from O, S, or NH;

or any pair of adjacent groups from R⁶ to R⁹ together form a group -O-(CH₂)_p-O-, where p is 1 or 2; and

R² is a naphthyl group, optionally substituted by one or more substituents selected from the group consisting of halo, C₁₋₇ alkyl, C₁₋₇ alkoxy, heterocyclyl having 3 to 20 ring atoms of which 1 to 10 are ring heteroatoms independently selected from the group consisting N, O and S and aryl or heteroaryl having 5 to 20 ring atoms, the heteroaryl groups having one or more heteratoms independently selected from the group consisting of N, O and S.

2. Cancelled.

3. Cancelled.

4. (Previously presented) A compound according to claim 1, wherein R⁹ is H.

5. (Previously presented) A compound according to claim 1, wherein R⁶ is H.

6. (Previously presented) A compound according to claim 1, wherein R⁷ and R⁸ (when the compound is not a dimer) are selected from OMe and OCH₂Ph.


7. Cancelled.

8. (Previously presented) A pharmaceutical composition containing a compound of claim 1, and a pharmaceutically acceptable carrier or diluent.

9. Cancelled.

10. (Previously presented) A method of treatment of melanomas, or breast, renal, or lung cancer, comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound of claim 1.

11. (Previously presented) A compound of formula (II)



wherein

R^2 is a naphthyl group, optionally substituted by one or more substituents selected from the group consisting of halo, C_{1-7} alkyl, C_{1-7} alkoxy, heterocyclyl having 3 to 20 ring atoms of which 1 to 10 are ring heteroatoms independently selected from the group consisting of N, O and S and aryl or heteroaryl having 5 to 20 ring atoms, the heteroaryl groups having one or more heteroatoms independently selected from the group consisting of N, O and S;

R^6 , R^7 and R^9 are independently selected from H, R, OH, OR, SH, SR, NH_2 , NHR, NRR' , nitro, Me_3Sn and halo;

R^8 is selected from H, R, OH, OR, SH, SR, NH_2 , NHR, NRR' , nitro, Me_3Sn and halo, or the compound is a dimer with each monomer being of formula (II), where the R^8 groups of each monomers form together a dimer bridge having the formula $-X-R''-X-$ linking the monomers, where R'' is a C_{3-12} alkylene group, which chain may be interrupted by one or more heteroatoms selected from the group consisting of O, S, and NH, and/or aromatic rings selected from the group consisting of benzene and pyridine, and each X is independently selected from O, S, or NH;

or any pair of adjacent groups from R^6 to R^9 together form a group $-O-(CH_2)_p-O-$, where p is 1 or 2;

R_{10} is selected from:

- (a) $4-NO_2-C_6H_4-CH_2-$;
- (b) $2-NO_2-$, 4,5-diMeO- $C_6H_4-CH_2-$;
- (c) $C_6H_5-CH_2-$; and

(d) $\text{Me-SO}_2\text{-C}_2\text{H}_4\text{-}$;

R_{11} is selected from OH, OR or SR; and

R and R' are independently selected from C_{1-7} alkyl, heterocyclyl having 3 to 20 ring atoms of which 1 to 10 are ring heteroatoms independently selected from the group consisting N, O and S and aryl or heteroaryl having 5 to 20 ring atoms, the heteroaryl groups having one or more heteratoms independently selected from the group consisting of N, O and S.

12. Cancelled.